GW Pharmaceuticals - Page 2 of 4

New data reinforces the efficacy and safety profile of cannabis in Multiple Sclerosis Spasticity

Posted on 09/10/2013 by Web Team |

London, UK; 2 October 2013: GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, “GW”) announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data…

GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy

Posted on 20/09/2013 by Web Team |

London, UK; 18 September 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW”) announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment…

New Study: Cannabis Can Help Grow Brain Cells

Posted on 25/08/2013 by Web Team |

A new study published recently in the journal Neurochemistry International has found that a compound in cannabis can help grow brain cells. “We tested three compounds: cannabidiol, cannabigerol, and cannabichromene…

Study Confirms Cannabis Has No Long-Term Negative Effect on Cognition

Posted on 05/08/2013 by Web Team |

London, UK, 5 August 2013: GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from…

Marijuana-Based Medicines Okayed in France

Posted on 12/06/2013 by Web Team |

At the behest of Social Affairs and Health Minister Marisol Touraine, France has modified its Public Health Code to allow for the use of marijuana-based medicines, apparently including raw marijuana…

GW Pharmaceuticals plc Announces Sativex® Commercialization Approval in Italy

Posted on 10/05/2013 by Web Team |

London, UK, 7 May 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary…

GW Pharmaceuticals Announces US Patent Allowance for SATIVEX Formulation Spray Device

Posted on 24/04/2013 by Web Team |

Porton Down, UK; 22 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced…

GW Pharmaceuticals’ cannabinoid-medicine Sativex moved to Schedule 4 of UK Drugs Act

Posted on 10/04/2013 by Web Team |

GW Pharmaceuticals, the biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced that Sativex®, its treatment for spasticity in Multiple Sclerosis, has…

GW Pharmaceuticals Announces New US Patent Allowance

Posted on 03/04/2013 by Web Team |

GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Patent and…

GW, Almirall may pull cannabis drug Sativex in German price row

Posted on 23/03/2013 by Web Team |

(Reuters) – GW Pharmaceuticals and Almirall may stop selling the cannabis drug Sativex in Germany after health authorities refused to agree a price that the companies view as acceptable. GW…

Sativex In Britain a video blog by Sarah Martin

Posted on 29/01/2013 by Web Team |

Sarah Martin the British representative for the International Association for Cannabinoid Medicines talks about Sativex and how it helps treat her symptoms of Multiple Sclerosis. Sativex is a cannabis…

The Drug Equality Alliance responds to the HASC Drugs Inquiry Report “Drugs: Breaking the Cycle”

Posted on 13/12/2012 by Web Team |

The Drug Equality Alliance has made multiple submissions to this inquiry from the outset; we have sought to demand a re-think about the errors of law within the terms of…

Results from GW Phase 11a Study Identify Promising New Oral Cannabinoid Anti-Diabetic Treatment

Posted on 28/11/2012 by Web Team |

Porton Down, UK; November 28 2012: GW Pharmaceuticals plc (AIM:GWP) reports results from a Phase IIa exploratory study which has identified GW’s novel cannabinoid, GWP42004, as a potential new oral…

GW Pharmaceuticals Preliminary Results for 2012

Posted on 28/11/2012 by Web Team |

Porton Down, UK, 28 November 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its preliminary results for the year…

New cannabis discovery could lead to better treatments for epilepsy

Posted on 13/09/2012 by Web Team |

Scientists at the University of Reading have demonstrated for the first time that a previously unstudied chemical in cannabis could lead to more effective treatments for people with epilepsy. The…

FREE WINSTON JAIL BAYER AG – MIDI Musical Intercourse

Posted on 24/03/2012 by Web Team |

Winston Matthews, 55, was sentenced to 16 months in HMP High Down for growing cannabis, proven to help his medical condition. Join the Free Winston Matthews group on Facebook Geoffrey…

Almirall granted commercial rights to Sativex for Mexican market

Posted on 16/03/2012 by Web Team |

GW Pharmaceuticals plc announces that it has signed an amendment to its Sativex® licence agreement with Almirall S.A. As part of the revised agreement, Almirall has been granted rights to…

Professor Vincenzo Di Marzo to direct GW’s global pre-clinical research programme

Posted on 09/03/2012 by Web Team |

Porton Down, UK; 8 March 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that, effective March 1st 2012, Professor Vincenzo Di Marzo has agreed to direct GW’s global pre-clinical research…

A man convicted of growing cannabis has failed in a High Court bid to have the drug granted equal classification with alcohol and tobacco

Posted on 10/02/2012 by Web Team |

Reading about this case (Cannabis campaign legal bid failure – U.TV) has been a very useful exercise indeed! James Torrens-Spence is to be commended for running this, and whilst he…

Sativex regulatory approval received in Austria

Posted on 08/02/2012 by Web Team |

Sativex® has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS). The launch of Sativex® in Austria is expected to take place during 2012…